Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel vs AR-targeted therapy in mCRPC
NCT02379390Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2015
- Primary completion
- May 2018
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Sanofi. Primary endpoint: Radiographic Progression-Free Survival up to 1059 days. Started Jun 2015; status: terminated.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02379390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02379390.